AcquisitionOther
Supernus Pharmaceuticals, Inc. acquired Sage Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Supernus Pharmaceuticals, Inc. -> Sage Therapeutics, Inc. · up to approximately $795 million
Strengthen neuropsychiatry portfolio with ZURZUVAE, the first and only FDA-approved oral treatment for postpartum depression.
Open source record (SEC) ↗